Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284009 | 0.86 | GRM1 (0.42) | SMN1; SMN2ALDH1A1NPC1RAB9AGRM1 | |
| SCHEMBL538229 | 0.85 | TDP1 (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL269136 | 0.83 | MEN1 (0.35) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL265399 | 0.81 | HTT (0.51) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL284094 | 0.77 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1NPC1RAB9AATM | |
| SCHEMBL27838280 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AGRM1 | |
| SCHEMBL264448 | 0.73 | TDP1 (0.44) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL2011432 | 0.72 | BRPF1 (0.43) | MEN1KMT2A | |
| SCHEMBL263494 | 0.72 | BACE1 (0.47) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL21573033 | 0.72 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | SMN1; SMN2 1166/4885ALDH1A1 986/4885NPC1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.